TVRD

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) is a clinical-stage biopharmaceutical company founded to develop innovative oral therapies for fibrosis-driven diseases. The company went public in April 2025 and focuses specifically on targeting the STAT3 pathway, a critical cellular signaling mechanism involved in inflammation and tissue scarring. Tvardi's approach centers on developing small molecule drugs that can be taken orally, offering potential advantages over injectable treatments commonly used in serious fibrotic conditions.